Form D · Biotechnology
Moonwalk Biosciences, Inc.
South San Francisco, CA · CIK 0002004362
Offering snapshot reported Sep 14, 2026 · SEC filing
- Reported sold
- $60M Offering amount: $70.2M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 26, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 14, 2026 | Initial | $59,999,998 | No comparison | 7 | SEC filing |
| Jan 2, 2024 | Initial | $49,574,983 | No comparison | 24 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-597380
Source: Form D, filed Sep 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alexander Aravanis | Director, Executive |
| Paul Burton | Director |
| Elaine Cheung | Executive |
| Chris Dimitropoulos | Director |
| Stephen Djedjos | Executive |
| Arash Jamshidi | Director, Executive |
| John Liles | Executive |
| Justin Valley | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2 Tower Place, 8 Th Floor
South San Francisco, CA, 94080
Phone: 650-540-9709
South San Francisco, CA, 94080
Phone: 650-540-9709